CMPX
HEALTHCARECompass Therapeutics Inc.
AI Insight
What's Moving CMPX Today?
No stock-specific AI insight has been generated for CMPX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.61$6.88
$2.06
Fundamentals
Market Cap$370M
P/E Ratio—
EPS$-0.40
Dividend Yield—
Dividend / Share—
ROE-46.0%
Profit Margin—
Debt / Equity—
Trading
Volume639K
Avg Volume (10D)—
Shares Outstanding180.1M
CMPX News
21 articles- How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer FilingYahoo Finance·Jun 17, 2026
- Compass Therapeutics Eyes FDA Path After Tovecimig Trial WinMarketbeat·Jun 8, 2026
- Compass Therapeutics to Participate in Upcoming June Investor EventsYahoo Finance·May 28, 2026
- Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual MeetingGlobeNewswire Inc.·May 21, 2026
- Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3MYahoo Finance·May 18, 2026
- Compass Therapeutics to Participate in Upcoming May Investor EventsYahoo Finance·May 12, 2026
- Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)Yahoo Finance·May 5, 2026
- Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate UpdateYahoo Finance·May 5, 2026
- Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity?Yahoo Finance·Apr 29, 2026
- Micron initiated, Rambus downgraded: Wall Street's top analyst callsYahoo Finance·Apr 28, 2026
- Compass Therapeutics’s stock crashes after OS miss in BTC trialClinicaltrialsarena·Apr 28, 2026
- Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARCYahoo Finance·Apr 28, 2026
- Compass Therapeutics Touts “Stunning” PFS Win in COMPANION-002 as Crossover Muddy OS DataMarketbeat·Apr 27, 2026
- This Biotech Stock Is Down 65%. How a Cancer Trial Was Ruined by Its Own Design.Yahoo Finance·Apr 27, 2026
- Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire Inc.·Apr 27, 2026
- Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract CancerYahoo Finance·Apr 27, 2026
- Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Path To ProfitabilityYahoo Finance·Apr 26, 2026
- Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract CancerGlobeNewswire Inc.·Apr 24, 2026
- Compass Therapeutics, Inc. (CMPX) Up 200% Year-on-YearYahoo Finance·Apr 21, 2026
- Will Psychedelic Stocks Have A Trippy Ride Under RFK Jr.?Yahoo Finance·Apr 2, 2026
- What Compass Therapeutics (CMPX)'s Pipeline Progress And 2025 Losses Reveal About Its Oncology StrategyYahoo Finance·Mar 9, 2026
All 21 articles loaded
Price Data
Open$2.06
Previous Close$2.06
Day High$2.10
Day Low$2.05
52 Week High$6.88
52 Week Low$1.61
52-Week Range
$1.61$6.88
$2.06
Fundamentals
Market Cap$370M
P/E Ratio—
EPS$-0.40
Dividend Yield—
Dividend / Share—
ROE-46.0%
Profit Margin—
Debt / Equity—
Trading
Volume639K
Avg Volume (10D)—
Shares Outstanding180.1M
About Compass Therapeutics Inc.
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—